Dupilumab

Study Highlights Critical Influence of AI-Driven Reputation on Pharma Market Leaders and New EntrantsCAMPBELL, Calif. and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), a pioneer in social-first digital engagement and integrated human-AI solutions, today released its inaugural AI Brand Reputation Index, providing unprecedented insight into how artificial intelligence shapes the perceptions of 50 leading pharmaceutical brands. The comprehensive study identifies key reputation drivers, revealing crucial implications for market leaders and emerging therapies alike. "As healthcare professionals, patients, and caregivers increasingly rely on AI-driven platforms for information, pharmaceutical brands must understand and actively manage their AI-driven reputations," said Peter Friedman, LiveWorld Chairman and CEO. "This index gives companies actionable insights to strategically enhance their brand positioning and ensure long-term success." Key Findings from the Report Include: Market Leaders Confirmed: Brands with high consumer familiarity and proven efficacy, such as Dupixent, and Keytruda, demonstrated robust AI reputations, driven by clinical effectiveness and healthcare professional trust.Advertising Not the Only Driver: Vertex Pharmaceuticals' Trikafta topped the rankings despite limited advertising, showcasing the power of clinical efficacy, healthcare provider endorsement, and authentic patient advocacy in building AI-driven brand perception.Challenges for New Therapies: Emerging drugs like Leqvio and Rybrevant struggle with AI visibility, highlighting immediate opportunities for strategic content marketing.Safety Perceptions Persist: Products with perceived safety concerns, such as Remicade and Xeljanz, face significant hurdles in AI-driven reputation, underscoring the lasting impact of safety profiles.Accessibility Matters: Brands recognized for affordability and patient-friendly access, including Farxiga and Jardiance, enjoyed enhanced AI-driven sentiment. The study utilizes LiveWorld’s proprietary AI framework assessing seven weighted reputation factors across prominent large language models (LLMs) including ChatGPT (GPT-4), Perplexity, and Grok. These factors encompassed efficacy, safety, healthcare professional trust, consumer sentiment, digital visibility, affordability, and patient loyalty. Based on the rankings, the study recommends strategic approaches for pharma companies to build up their brand reputation starting with investing in AI-powered brand monitoring and continuous reputation management. "AI-driven reputation management is no longer optional—it is a strategic imperative," added Friedman. "Brands that proactively engage with their AI presence will significantly outperform their competition." Helpful Links: LiveWorld AI Brand Reputation Index for Pharma Top 50 BrandsBrands interested in requesting a customized AI brand reputation report for their brand with competitive comparisons may contact us here. About LiveWorld LiveWorld is a social-first digital agency and software company that unlocks the full potential of social media to transform customer relationships through integrated compliance, engagement, and insight solutions. We provide brand marketers bold creative rooted in strategy that captivates and resonates, social moderation and engagement that activates interactions, software that enriches customer experiences, and compliance that enables and accelerates digital programs. With over 28 years of making connections, we leverage our social media DNA to deliver emotion-driven behavior change through digital campaigns with a human touch. LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in Campbell, California, with an additional office in New York City. Learn more at www.liveworld.com and @LiveWorld. LiveWorld ContactPR Contact:Matthew HammerLiveWorldmhammer@liveworld.com(737) 212-9739

Sanofi’s efforts to explore its OX40-ligand targeting drug for inflammatory diseases other than eczema have hit a roadblock as the drug failed a Phase 2 trial in patients with asthma. The French drugmaker obtained the candidate, dubbed amlitelimab, as part of its $1.45 billion buyout of Kymab in 2021. The highest dose of amlitelimab missed the Phase 2 trial’s primary endpoint of an annualized rate of severe flare-ups at 48 weeks, according to preliminary results shared Tuesday. The medium and low doses of the drug seemed to perform better on the same measure, but because the highest dose missed the mark, those data had only “nominal significance.” The placebo-controlled Phase 2 TIDE-Asthma trial tested amlitelimab as an add-on to standard of care in 448 people with moderate to severe asthma. Results from the study were initially expected towards the end of last year but were pushed back in October to the first half of 2025. The delay raised the suspicions of Leerink analysts, who wrote they were “cautious” about the readout last month. Sanofi maintained that some parts of the Phase 2 data suggest there’s still a path forward in asthma. The medium dose of amlitelimab produced “nominally significant and clinically meaningful reductions” in severe flare-ups at 60 weeks in a subgroup of patients with heterogeneous inflammatory disease, the company said. If these results are replicated in later studies, they could represent a “breakthrough” for this population, Sanofi claimed. Sanofi is planning a Phase 3 program for amlitelimab in asthma. But the product’s most advanced indication is atopic dermatitis, which is being evaluated in the Phase 3 OCEANA program. Last month, Sanofi shared updated Phase 2 data showing the drug improved eczema symptoms through 28 weeks. The OX40-ligand drug is designed for quarterly dosing after an initial loading dose, giving it a potential convenience advantage over more frequently administered eczema treatments, including Sanofi’s own Dupixent. Sanofi also noted on Tuesday that it has kicked off two Phase 3 and one Phase 2 trial of its Regeneron-partnered IL‐33 targeting drug, itepekimab, in chronic rhinosinusitis. Itepekimab is also in a pair of Phase 3 studies in chronic obstructive pulmonary disease, with readouts expected in the second half of this year. The company also expects to start a Phase 2/3 COPD trial of its dual IL-13/TSLP inhibitor, lunsekimig, this year.